Esperion Therapeutics Inc.
ESPR
Get informed when a big investor buys or sells
+ FollowMarket Cap$661.15M
Close$
$11.14
250.2% upside
Current Fair Value
250.2% upsideUndervalued by 250.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $661.15 Million |
|---|---|
| Enterprise Value | $801.15 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.11 |
| Beta | 1.06 |
| Outstanding Shares | 251,353,086 |
Return
| Return on Equity | -0.17% |
|---|---|
| Return on Assets | 0.11% |
| Return on Invested Capital | 47.14% |
Valuation & Multiples
| P/E Ratio | -131.4 |
|---|---|
| PEG | 348.38 |
| Price to Sales | 3.18 |
| Price to Book Ratio | -1.59 |
| Enterprise Value to Revenue | 1.92 |
| Enterprise Value to EBIT | 10.48 |
| Enterprise Value to Net Income | 1567 |
| Total Debt to Enterprise | 0.37 |
| Debt to Equity | -0.96 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$106.06 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$92.48 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 25.93% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.89%▼ 83.01% |
|---|---|
| Total Invested | $6.99M▼ 98.54% |
| Investors Holding | 6▼ 212.00% |
ESG Score
No data
About Esperion Therapeutics Inc.
CEO: Timothy Mayleben